Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil added to Pirfenidone in Advanced IPF
NCT02951429Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH) comparing Pirfenidone + Sildenafil with Pirfenidone + Placebo (2 arms). Primary endpoint: Percentage of Participants With Disease Progression at 52 weeks. Started Dec 2016; status: completed.
02
Drugs
sildenafil
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02951429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951429.